Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
m (type) |
mNo edit summary |
||
| Line 1: | Line 1: | ||
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases | Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases | ||
<gallery> | This fibrate reduce triglyceride and riseHDL-cholesterol<ref>How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?</ref><gallery> | ||
File:4528-62340-1-PB.jpg</gallery> | File:4528-62340-1-PB.jpg | ||
</gallery> | |||
<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599574/ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis]</ref> | <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599574/ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis]</ref> | ||
<ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | <ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | ||
Revision as of 00:19, 5 November 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases
This fibrate reduce triglyceride and riseHDL-cholesterol[1]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure)
- ↑ How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?
- ↑ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
- ↑ Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis